Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21;13(5):571-576.
doi: 10.1021/acsmacrolett.4c00119. Epub 2024 Apr 22.

Caspase-3-Responsive, Fluorogenic Bivalent Bottlebrush Polymers

Affiliations

Caspase-3-Responsive, Fluorogenic Bivalent Bottlebrush Polymers

Hadiqa Zafar et al. ACS Macro Lett. .

Abstract

Controlling the access of proteases to cleavable peptides placed at specific locations within macromolecular architectures represents a powerful strategy for biologically responsive materials design. Here, we report the synthesis of peptide-containing bivalent bottlebrush (co)polymers (BBPs) featuring polyethylene glycol (PEG) and 7-amino-4-methylcoumarin (AMC) pendants on each backbone repeat unit. The AMCs are linked via caspase-3-cleavable peptides which, upon enzymatic cleavage, provide a "turn-on" fluorescence signal due to the release of free AMC. Time-dependent fluorscence measurements demonstrate that the caspase-3-induced peptide cleavage and AMC release from BBPs is strongly dependent on the BBP backbone length and the AMC-peptide linker location within the BBP architecture, revealing fundamental insights into the interactions of enzymes with BBPs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
A) Previous works using bivalent MMs for BBP synthesis via “graft-through” ROMP. B) Bivalent, peptide-based BBPs designed to probe enzyme access quantitatively by fluorescence.
Figure 2.
Figure 2.
Synthesis of DEVD-MM. Inset: MALDI-TOF spectrum for DEVD-MM. C191H344N11O85: Calculated: 4154.85; Found: 4154.62 [M + H+]. C191H343N11O85Na: Calculated: 4176.83; Found: 4176.60 [M + Na]+.
Figure 3.
Figure 3.
A) SEC traces of DEVD-MM, DP10, DP20, and DP30 BBPs. B) Representative DLS measurements for DP10. C) SEC traces for triblock copolymers MID and END as well as each intermediate toward their synthesis. MID-1 and END-1 refer to the first blocks of MID and END, respectively; MID-2 and END-2 refer to the diblock copolymers formed after addition of a 2nd block to MID-1 and END-1, respectively. The shifts to shorter retention times upon transitioning from MID-1 to MID-2 to MID, and END-1 to END-2 to END, and the trace unreacted MM in each case, are consistent with high conversions of each block.” D) Representative DLS measurements for MID.
Figure 4.
Figure 4.
A) Hypothesized relative rates of peptide linker cleavage (for estimates based on fraction of end-groups see Table 2S). B) Fluorescence “turn-on” versus time for all BBPs (left) and zoomed in view of the same data (right). Release conditions with and without carrier-free, recombinant human CASP3 addition were: pH 7.4, 50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1mM EDTA, 10% glycerol (CASP3 assay buffer).

Similar articles

Cited by

  • Antibody-bottlebrush prodrug conjugates for targeted cancer therapy.
    Liu B, Nguyen HV, Jiang Y, Wang AX, Lensch V, Sun Z, Boyer ZH, Raftopoulos PA, Dai Y, MacNicol PL, Wang Y, Jyotsana N, Wang W, Bhagchandani S, Hemdev S, Shieh P, Kristufek SL, Boucher M, Downes M, Evans RM, MacMillan DWC, Johnson JA. Liu B, et al. Nat Biotechnol. 2025 Sep 9. doi: 10.1038/s41587-025-02772-z. Online ahead of print. Nat Biotechnol. 2025. PMID: 40925997

References

    1. Chagri S; Ng DYW; Weil T Designing bioresponsive nanomaterials for intracellular self-assembly. Nat. Rev. Chem 2022, 6, 320–338. - PMC - PubMed
    1. Cao Z; Li W; Liu R; Li X; Li H; Liu L; Chen Y; Lv C; Liu Y pH-and enzyme-triggered drug release as an important process in the design of anti-tumor drug delivery systems. Biomed. Pharmacother 2019, 118, 109340. - PubMed
    1. Li Y; Zhang C; Li G; Deng G; Zhang H; Sun Y; An F Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy. Act. Pharm. Sin. B 2021, 11, 2220–2242. - PMC - PubMed
    1. Liwinska W; Waleka-Bagiel E; Stojek Z; Karbarz M; Zabost E Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels. Drug Deliv. 2022, 29, 2561–2578. - PMC - PubMed
    1. Son J; Parveen S; Macpherson D; Marciano Y; Huang RH; Ulijn RV MMP-responsive nanomaterials. Biomater. Sci 2023, 11, 6457. - PubMed

Publication types

LinkOut - more resources